Blog
RSS FeedPosted by Michael Wonder on 18 Oct 2024
Government of Canada announces new appointment to the Patented Medicine Prices Review Board
17 October 2024 - Today, the Honourable Mark Holland, Minister of Health, announced a new appointment to the Patented Medicine ...
Posted by Michael Wonder on 20 Sep 2024
BioCryst and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Orladeyo (berotralstat), an oral, once daily therapy for the prevention of hereditary angioedema attacks
17 September 2024 - BioCryst Pharmaceuticals today announced that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for oral, ...
Posted by Michael Wonder on 04 Sep 2024
Lilly Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Omvoh (mirikizumab) for adults with moderately to severely active ulcerative colitis
3 September 2024 - Eli Lilly Canada announced today that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for Omvoh ...
Posted by Michael Wonder on 16 Aug 2024
First public drug plans provide reimbursement for Camzyos for adults with symptomatic obstructive hypertrophic cardiomyopathy
15 August 2024 - BMS Canada is pleased to announce an important milestone for eligible patients with symptomatic obstructive hypertrophic ...
Posted by Michael Wonder on 30 Jul 2024
HLS announces reimbursement for Vascepa under Alberta's Provincial Drug Plan
29 July 2024 - With the addition of Alberta's public plan, Vascepa will be available to more than 90% of ...
Posted by Michael Wonder on 18 Jul 2024
BC doctor calls on the province to cover obesity medications
17 July 2024 - A petition from Dr. Ali Zentner asking for more PharmaCare coverage has received almost 1,000 signatures. ...
Posted by Michael Wonder on 27 Jun 2024
Expanding our scientific advice services for the life sciences sector in Canada
26 June 2024 - Canada’s Drug Agency is launching a new one year learning period in our Scientific Advice program ...
Posted by Michael Wonder on 01 Jun 2024
New analysis examines role of conditional approvals on access to promising oncology therapies
31 May 2024 - Health Canada’s Notice of Compliance with conditions (NOC/c) policy has been effective in providing people in Canada ...
Posted by Michael Wonder on 30 May 2024
Improving our assessments of drugs with companion diagnostic tests
30 May 2024 - As part of our ongoing initiative to improve and modernise our reimbursement review program, Canada’s Drug Agency ...
Posted by Michael Wonder on 28 May 2024
The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort study
27 May 2024 - The Patented Medicine Prices Review Board (PMPRB), the agency that regulates the prices of patented medicines in ...
Posted by Michael Wonder on 25 May 2024
Moving forward on Pharmacare for Canadians
24 May 2024 - Pharmacare legislation includes universal access to contraception and diabetes medications. ...
Posted by Michael Wonder on 24 May 2024
Bausch Health announces additional public drug plan listings for Uceris (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults
23 May 2024 - Bausch Health today announced additional Canadian public drug plan listings for Uceris (budesonide) aerosol foam to ...
Posted by Michael Wonder on 23 May 2024
PMPRB report examines availability and pricing of new medicines
22 May 2024 - The Patented Medicine Prices Review Board (PMPRB) published the eighth edition of its annual Meds Entry Watch ...
Posted by Michael Wonder on 22 May 2024
The National Advisory Committee on Immunization recommends Beyfortus to protect all infants against RSV
21 May 2024 - The National Advisory Committee on Immunization issued a recommendation for Beyfortus (nirsevimab) to be used for the ...
Posted by Michael Wonder on 10 May 2024
When will Canada have national pharmacare?
22 April 2024 - Canadians support it, public health demands it, now policy makers must deliver it. ...